Company Insights

DNA customer relationships

Explore interactive graphBrowse insights index
DNA customer relationship map

Ginkgo Bioworks (DNA): customer map and why it matters to investors

Ginkgo Bioworks monetizes a platform for cell engineering and biosecurity by contracting with governments, large enterprises, and emerging companies to deliver laboratory automation, strain development, and recurring data and analytics services. Revenue mixes include fixed‑scope engineering projects, multi‑year collaborations, and an expanding subscription component (Canopy) for recurring data and analytics, with meaningful non‑cash recognition events when contracts terminate. For investors evaluating customer risk and runway, the interplay of large government awards, strategic enterprise partners, and legacy related‑party arrangements defines both upside and concentration risk.
Explore deeper coverage at https://nullexposure.com/.

How Ginkgo sells its platform to real customers

Ginkgo operates as a hybrid service provider and licensor across two commercial segments: cell engineering services and biosecurity services. Key operating characteristics that shape revenue and risk:

  • Contracting posture: a mix of short‑term engineering projects (six–12 month RAC deployments), fixed‑price spot engagements for discrete scope work, and growing subscription revenue from the Canopy program. This combination creates near‑term variability with emergent recurring revenue.
  • Customer concentration and geography: revenue is concentrated and U.S.‑centric — three customers represented more than 10% of revenue in 2024 and ~81% of revenue derives from the U.S. — while government contracts add global strategic exposure.
  • Role and maturity: Ginkgo functions both as a buyer‑facing service provider and as an IP licensor to partners; several IP agreements and related‑party arrangements affect both cash flows and reported revenue recognition.
  • Materiality and spend posture: the company serves government and large enterprise clients as primary payers, while many commercial engagements fall into the $1–10M spend band or below.

These traits explain why large government awards and a handful of enterprise partners dominate the investment thesis.

Customer relationships — who’s on Ginkgo’s roster and what they pay for

Below I summarize every named customer or partner in Ginkgo’s customer results with the source that documents the relationship.

Joyn Bio

Ginkgo recorded $2.9 million of services revenue from Joyn Bio and received a $20 million nonrefundable prepayment under the Joyn Bio FSA, per Ginkgo’s FY2024 Form 10‑K, indicating a sizable prepaid engineering engagement. (Ginkgo FY2024 10‑K)

Pacific Northwest National Laboratory (PNNL)

Management announced a $47 million contract to build an autonomous lab and described dedicated instrument systems delivered to PNNL as proof points for scaling autonomous labs. (2025 Q4 earnings call; industry news coverage March 2026)

ARPA‑H

Ginkgo cited ARPA‑H among new government‑level engagements that are converting into repeat data‑generation business with top pharma customers, signaling strategic biosecurity and translational research work. (2025 Q4 earnings call)

Google Cloud

Ginkgo entered a five‑year strategic cloud and AI partnership (Aug 29, 2023) to develop and deploy AI tools for biology and biosecurity, anchoring the company’s compute and data strategy. (Ginkgo FY2024 10‑K)

U.S. Department of Energy

Ginkgo disclosed a $47 million DOE‑related contract to build a 97‑robot autonomous lab at PNNL, highlighting federal investment in laboratory automation. (2025 Q4 earnings call)

Environmental Molecular Sciences Laboratory (EMSL) at PNNL

News coverage reported a four‑year, up to $47M award to co‑design and integrate a High‑Throughput Automated Phenotyping Platform for the DOE M2PC program. (StockTitan / March 2026 news)

Invaio Sciences

As part of commercialization for peptide agricultural products, Invaio will leverage Ginkgo’s platform and microbial strains for protein production, positioning Ginkgo as a manufacturing and R&D partner. (InvestingNews March 2026)

European Health and Digital Executive Agency (HaDEA)

Ginkgo announced a collaboration under a joint tender up to €24M to deliver next‑generation point‑of‑care diagnostics, where HaDEA acted as contracting authority. (PR Newswire, FY2025)

Syngenta Crop Protection

Ginkgo and Syngenta launched a collaboration to accelerate a biological crop protection solution, with Ginkgo optimizing microbial strains for production targets. (Company disclosure summarized in sector reporting, FY2024)

XpresSpa

Market commentary indicates a partnership enabling Ginkgo to provide biological testing and monitoring services in travel environments, opening a commercial channel into physical testing services. (TradingView community commentary, FY2026)

BiomEdit, Inc.

Ginkgo recognized $7.5 million in non‑cash revenue from the release of deferred revenue tied to a terminated BiomEdit contract, reflecting contract termination accounting effects. (SEC 8‑K reporting summarized via StockTitan, FY2026)

Great Lakes Bioenergy Research Center

Ginkgo will deploy a flexible laboratory automation system to support biofuels and bioproducts research, reinforcing the company’s footprint in national research centers. (SimplyWall.St reporting, FY2025)

Lesaffre et Compagnie, SA

Lesaffre acquired ALTAR from Ginkgo on Oct 8, reflecting an asset sale or IP transfer in the industrial yeast/fermentation space. (SimplyWall.St, FY2025)

Tower Biosecurity, Inc.

Ginkgo agreed to transfer all issued and outstanding equity of Ginkgo Biosecurity, LLC to Tower Biosecurity under a Stock Purchase Agreement, a strategic divestiture of its biosecurity subsidiary. (SEC 8‑K via StockTitan, FY2026)

Inductive Bio

Ginkgo, Tangible Scientific, and Inductive Bio configured lab‑in‑the‑loop workflows where computational designs are validated experimentally by Ginkgo, enabling closed‑loop R&D. (SahmCapital release, 2025)

Motif FoodWorks (and Motif / Motif related party)

Ginkgo holds equity ties and long‑standing contracts with Motif; FY2024 included $45.4M recognized on termination of Motif contracts and additional deferred revenue releases, underscoring that related‑party arrangements have material accounting impacts. (SEC 8‑K and StockTitan reports, FY2026 disclosures)

OpenAI

Ginkgo reported a collaboration where OpenAI used GPT‑5 to design experiments executed in Ginkgo’s cloud lab, demonstrating integration of advanced generative AI into experimental design workflows. (SEC 8‑K summarized via StockTitan, FY2026)

Bolt Threads

Ginkgo partnered with Bolt Threads to scale synthetic spider silk production, underscoring industrial biotech commercial collaborations. (TradingView community reporting, FY2026)

Roche

Sector commentary lists Roche among large pharmaceutical partners providing R&D funding and recurring program revenue for Ginkgo’s services. (TradingView sector commentary, FY2026)

Bayer / Bayer Crop Science

Bayer has been described as an anchor agricultural customer in a major multi‑year collaboration (Joyn/expanded platform) and Ginkgo reported extensions of its multi‑year partnership with Bayer as part of its commercial momentum. (PR Newswire FY2022; market reporting FY2025)

Biogen

Biogen is listed among large biotech partners that contribute R&D funding and program revenue to Ginkgo’s pipeline of collaborations. (TradingView sector commentary, FY2026)

IARPA

Public reporting ties Ginkgo to defense‑adjacent work under programs like IARPA to develop controls preventing misuse of sequence ordering, consistent with biosecurity capabilities. (TradingView commentary, FY2026)

Cronos

Commentary indicates work to engineer yeast to produce THC precursors for Cronos, representing a contract in specialty biosynthesis. (TradingView community commentary, FY2026)

What these relationships imply for operations and investors

Collectively, the customer set demonstrates three investment‑relevant dynamics:

  • Concentration and materiality: three customers represented over 10% of revenue in 2024, meaning large awards (like DOE/PNNL and major enterprise partners) materially move top line and reported earnings. (Company 10‑K disclosure)
  • Mixed contract economics: Ginkgo’s business combines short‑term RAC system build cycles (6–12 months), fixed‑scope spot work, and a growing subscription base through Canopy that improves revenue predictability over time. (Company disclosures on contract types)
  • Government and large‑enterprise criticality: governments are primary biosecurity customers while large enterprise R&D programs drive higher‑value multi‑year work; both customer types create strategic endorsement but also create concentration risk. (10‑K biosecurity and customer mix notes)

Separately, Ginkgo acts as an IP licensor in named agreements (Motif and BiomEdit are explicitly referenced in the company’s IP agreement disclosures), which creates an additional revenue and balance‑sheet channel distinct from service delivery. (10‑K IP agreement excerpts)

Explore interactive customer analytics at https://nullexposure.com/.

Investment takeaway and next steps for due diligence

Ginkgo’s commercial footprint combines large, government‑funded automation contracts and enterprise R&D partnerships with a growing subscription layer. That structure drives both scalability—through repeat data work with top pharma and government labs—and volatility—through concentrated customers and accounting effects from contract terminations. Key investor levers are traction in recurring Canopy revenue, execution on autonomous lab rollouts (PNNL/DOE work), and the stabilization of related‑party contract exposures.

For a focused look at counterparty exposures, revenue recognition drivers, and contract timelines, review Ginkgo’s filings and curated relationship summaries at https://nullexposure.com/.